Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMPA-AHF
NCT05392764Phase 3Recruiting
- Sponsor
- Juntendo University
- Start
- Sep 2022
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Acute Heart Failure (AHF) comparing Empagliflozin with Placebo (2 arms). Primary endpoint: Hierarchical composite endpoint of death, heart failure rehospitalization, WHF, and urine output at 90 days. Started Sep 2022; status: recruiting.
02
Drugs
empagliflozin
03
Conditions
Acute Heart Failure (AHF)
Beyond the preview
Go deeper on NCT05392764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05392764.